A multi-center open-labeled study of recombinant erythropoietin-β in the treatment of anemic patients with multiple myeloma, low-grade non-Hodgkin’s lymphoma, or chronic lymphocytic leukemia in Chinese population

[1]  Y. Brandberg,et al.  Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  J. Groopman,et al.  Chemotherapy-induced anemia in adults: incidence and treatment. , 1999, Journal of the National Cancer Institute.

[3]  G. Salles,et al.  Frequency and significance of anemia in non-Hodgkin's lymphoma patients. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  J. S. San Miguel,et al.  Recombinant human erythropoietin in the anaemia of multiple myeloma and non-Hodgkin's lymphoma. , 1998, Medical oncology.

[5]  N. Thatcher.  Management of chemotherapy-induced anemia in solid tumors. , 1998, Seminars in oncology.

[6]  J. Y. Lee,et al.  Epoetin alpha and beta in their erythropoetin isoform compositions and biological properties , 1998 .

[7]  G. Browman,et al.  Erythropoietin in the management of patients with nonhematologic cancer receiving chemotherapy. Systemic Treatment Program Committee. , 1997, Cancer prevention & control : CPC = Prevention & controle en cancerologie : PCC.

[8]  G. Juliusson,et al.  Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma--a randomized multicenter study. The European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin's Lymphoma. , 1996, Blood.

[9]  R. Friedberg.  Issues in transfusion therapy in the patient with malignancy. , 1994, Hematology/oncology clinics of North America.

[10]  L. Jensen,et al.  Reduced production, absorption, and elimination of erythropoietin in uremia compared with healthy volunteers. , 1994, Journal of the American Society of Nephrology : JASN.

[11]  J. Cummings,et al.  Vascular subcortical dementias: clinical aspects. , 1994, Dementia.

[12]  M. Colleoni,et al.  Recombinant-human-erythropoietin (rhuepo) in the treatment of anemia associated with solid tumors with or without bone-marrow infiltration. , 1993, International journal of oncology.

[13]  H. Ludwig,et al.  Erythropoietin treatment for chronic anemia of selected hematological malignancies and solid tumors. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  Abels Ri,et al.  Use of recombinant human erythropoietin in the treatment of anemia in patients who have cancer. , 1992, Seminars in oncology.

[15]  S. L. Chang,et al.  The effect of recombinant human erythropoietin on hemostatic status in chronic uremic patients. , 1992, International journal of hematology.

[16]  H. Gisslinger,et al.  Erythropoietin treatment of anemia associated with multiple myeloma. , 1990, The New England journal of medicine.

[17]  H. Ludwig.  Epoetin in cancer-related anaemia. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[18]  W. Jelkmann,et al.  Serum erythropoietin and creatinine concentrations as predictive factors for response to recombinant human erythropoietin treatment in anaemic tumour patients on chemotherapy. , 1998, Oncology reports.

[19]  R. Means.  Pathogenesis of the anemia of chronic disease: A cytokine‐mediated anemia , 1995, Stem cells.

[20]  H. Ludwig,et al.  Recombinant human erythropoietin for the treatment of chronic anemia in multiple myeloma and squamous cell carcinoma , 1993, Stem cells.